Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

China Outlook: Further Weakness in the Economy?
56:59 - Raymond Chan, Asia-Pacific chief investment officer at Allianz Global Investors, discusses Asian markets in 2016, the outlook for China's economy and where he sees opportunity. He speaks to Bloomberg's Angie Lau on "First Up." (Source: Bloomberg)
  • TransCanada Among Winners From Alberta's Carbon Policy
  • Fidelity's Brown: ECB to Cut in Early December
  • Trudeau Extends Timeline on Canada Refugee Resettlement